1. Home
  2. EVH vs SNDX Comparison

EVH vs SNDX Comparison

Compare EVH & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVH
  • SNDX
  • Stock Information
  • Founded
  • EVH 2011
  • SNDX 2005
  • Country
  • EVH United States
  • SNDX United States
  • Employees
  • EVH N/A
  • SNDX N/A
  • Industry
  • EVH Other Consumer Services
  • SNDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVH Consumer Discretionary
  • SNDX Health Care
  • Exchange
  • EVH Nasdaq
  • SNDX Nasdaq
  • Market Cap
  • EVH 1.2B
  • SNDX 1.1B
  • IPO Year
  • EVH 2015
  • SNDX 2016
  • Fundamental
  • Price
  • EVH $8.35
  • SNDX $11.45
  • Analyst Decision
  • EVH Strong Buy
  • SNDX Strong Buy
  • Analyst Count
  • EVH 14
  • SNDX 11
  • Target Price
  • EVH $16.79
  • SNDX $35.91
  • AVG Volume (30 Days)
  • EVH 2.3M
  • SNDX 2.5M
  • Earning Date
  • EVH 05-08-2025
  • SNDX 07-31-2025
  • Dividend Yield
  • EVH N/A
  • SNDX N/A
  • EPS Growth
  • EVH N/A
  • SNDX N/A
  • EPS
  • EVH N/A
  • SNDX N/A
  • Revenue
  • EVH $2,398,737,000.00
  • SNDX $43,722,000.00
  • Revenue This Year
  • EVH N/A
  • SNDX $426.77
  • Revenue Next Year
  • EVH $16.14
  • SNDX $98.31
  • P/E Ratio
  • EVH N/A
  • SNDX N/A
  • Revenue Growth
  • EVH 10.24
  • SNDX N/A
  • 52 Week Low
  • EVH $7.06
  • SNDX $8.58
  • 52 Week High
  • EVH $33.63
  • SNDX $25.07
  • Technical
  • Relative Strength Index (RSI)
  • EVH 48.11
  • SNDX 54.49
  • Support Level
  • EVH $7.15
  • SNDX $10.52
  • Resistance Level
  • EVH $8.64
  • SNDX $11.41
  • Average True Range (ATR)
  • EVH 0.44
  • SNDX 0.66
  • MACD
  • EVH 0.08
  • SNDX 0.22
  • Stochastic Oscillator
  • EVH 72.27
  • SNDX 88.24

About EVH Evolent Health Inc

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: